Companies Sage Therapeutics

Sage Therapeutics (SAGE): executive pay, fiscal 2024

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Sage Therapeutics’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$7,112,589CEO Barry Greene · source

Say-on-pay support76.72%Latest vote · source

CEO vs. named peers20th pct.Of 40 peer CEOs

CEO pay ratio19:1To the median employee · source

CEO pay, last three years

$5,705,164FY2022
$6,237,491FY2023
$7,112,589FY2024

CEO total pay was $7,112,589 in fiscal 2024, up from $6,237,491 in fiscal 2023.

FY2024: salary $830,712 · bonus $0 · stock awards $3,164,364 · option awards $2,669,263

Executives and directors

Barry Greene · CEO Anne Marie Cook · General Counsel Kimi Iguchi · CFO Laura Gault · Chief Medical Officer Elizabeth Barrett · Independent Director Geno Germano · Independent Director George Golumbeski · Independent Director James M. Frates · Independent Director Jeffrey M. Jonas · Independent Director Jessica Federer · Independent Director Kevin P. Starr · Independent Director Michael F. Cola · Independent Director Steven Paul · Independent Director

Frequently asked questions

Who was the highest-paid executive at Sage Therapeutics in fiscal 2024?

As disclosed, Barry Greene (Chief Executive Officer and President) was the highest-paid executive at Sage Therapeutics in fiscal 2024, with total compensation of $7,112,589.

How does Sage Therapeutics's chief executive pay compare to its disclosed peer group?

As disclosed, Barry Greene's total compensation ranked at the 20th percentile of Sage Therapeutics's disclosed peer group.

What is Sage Therapeutics's CEO-to-median employee pay ratio?

As disclosed, Sage Therapeutics's CEO-to-median employee pay ratio was 19:1.

How did shareholders vote on Sage Therapeutics's executive compensation?

As disclosed, 76.72% of shareholders supported Sage Therapeutics's executive compensation in the latest say-on-pay vote.

How much does Sage Therapeutics spend in total on board compensation for fiscal 2024?

As disclosed, Sage Therapeutics reported total board compensation of $562,594 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Barry Greene	$830,712	$0	$3,164,364	$2,669,263	$431,970	$0	$16,280	$7,112,589
Chief Executive Officer and President
Kimi Iguchi	421,260	0	1,542,448	361,447	0	0	742,520	3,067,675
Former Chief Financial Officer and Treasurer
Christopher Benecchi	532,236	40,000	1,365,700	481,488	179,200	0	6,364	2,604,988
Chief Operating Officer and Treasurer
Anne Marie Cook	430,329	0	1,106,573	359,373	0	0	685,435	2,581,710
Former Senior Vice President, General Counsel and Secretary
Laura Gault	550,174	0	1,106,573	357,531	176,056	0	12,719	2,203,053
Former Chief Medical Officer
Gregory Shiferman	435,467	20,000	99,310	453,013	152,000	0	9,878	1,169,668
Senior Vice President, General Counsel and Secretary

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2024 total	FY2023 total	FY2022 total	Δ FY2023→2024
Barry Greene	$7,112,589	$6,237,491	$5,705,164	↑ +875,098
Kimi Iguchi	3,067,675	1,984,101	1,624,967	↑ +1,083,574
Christopher Benecchi	2,604,988	2,280,917	1,865,704	↑ +324,071
Anne Marie Cook	2,581,710	2,150,623	1,671,197	↑ +431,087
Laura Gault	2,203,053	1,274,325	3,967,795	↑ +928,728
Gregory Shiferman	1,169,668	1,318,968	686,376	↓ −149,300

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The company maintains a strong pay-for-performance orientation by making a significant portion of total compensation variable and dependent on performance against goals, differentiating awards based on individual performance, and tying the vesting of certain PSU awards to specified TSR milestones to align executive interests with stockholder return.

CEO STI target (% of salary)	150%
CEO LTI target (% of salary)	—
Independent consultant	Alpine Rewards
Clawback policy	true
Anti-hedging	true
Anti-pledging	true

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2024

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Senior Vice	PSU	2024-02-13	—	3,000	—	3,000	$69,060
Christopher Benecchi	OPTION	2024-02-13	—	—	27,000	—	429,022
Christopher Benecchi	PSU	2024-02-13	—	13,500	—	13,500	310,770
Christopher Benecchi	PSU	2024-02-13	—	8,100	—	16,200	271,269
Christopher Benecchi	OPTION	2024-11-01	—	—	12,500	—	52,466
Anne Marie Cook	OPTION	2020-04-28	—	—	9,450	—	1,351,350
Anne Marie Cook	PSU	2024-02-13	—	6,750	—	13,500	226,058
Anne Marie Cook	OPTION	2022-02-11	—	—	10,133	—	1,134,896
Anne Marie Cook	OPTION	2015-09-16	—	—	109,300	—	41,096,800
Anne Marie Cook	PSU	2024-02-13	—	27,000	—	27,000	621,540
Laura Gault	PSU	2024-02-13	—	6,750	—	13,500	226,058
Laura Gault	OPTION	2024-02-13	—	—	22,500	—	357,531
Barry Greene	PSU	2024-02-13	—	25,200	—	50,400	843,948
Gregory Shiferman	OPTION	2024-02-21	—	—	20,608	—	314,942
Senior Vice	OPTION	2024-02-13	—	—	6,000	—	95,345
Christopher Benecchi	PSU	2024-11-01	—	6,250	—	6,250	37,813
Anne Marie Cook	PSU	2024-02-13	—	11,250	—	11,250	258,975
Gregory Shiferman	PSU	2024-02-13	—	3,000	—	3,000	69,060
Christopher Benecchi	PSU	2024-02-13	—	32,400	—	32,400	745,848
Senior Vice	OPTION	2024-02-21	—	—	20,608	—	314,942
Laura Gault	PSU	2024-02-13	—	27,000	—	27,000	621,540
Laura Gault	PSU	2024-02-13	—	11,250	—	11,250	258,975
Barry Greene	PSU	2024-02-13	—	100,800	—	100,800	2,320,416
Kimi Iguchi	PSU	2024-02-13	—	27,000	—	27,000	703,620
Gregory Shiferman	PSU	2024-11-01	—	5,000	—	5,000	30,250
Anne Marie Cook	OPTION	2017-02-06	—	—	46,480	—	15,477,840
Barry Greene	OPTION	2024-02-13	—	—	168,000	—	2,669,263
Gregory Shiferman	OPTION	2024-11-01	—	—	10,000	—	42,726
Anne Marie Cook	OPTION	2021-02-10	—	—	17,417	—	156,753
Anne Marie Cook	OPTION	2016-02-08	—	—	15,000	—	11,655,000
Anne Marie Cook	OPTION	2023-02-13	—	—	7,917	—	562,107
Anne Marie Cook	OPTION	2024-02-13	—	—	22,500	—	357,526
Anne Marie Cook	OPTION	2020-02-12	—	—	20,000	—	520,000
Gregory Shiferman	OPTION	2024-02-13	—	—	6,000	—	95,345
Anne Marie Cook	OPTION	2019-02-13	—	—	19,000	—	—
Anne Marie Cook	OPTION	2018-04-02	—	—	15,750	—	—

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Senior Vice	$0	$69,060	$410,287	14.4%
Christopher Benecchi	0	1,365,700	481,488	73.9%
Anne Marie Cook	0	1,106,573	72,312,272	1.5%
Laura Gault	0	1,106,573	357,531	75.6%
Barry Greene	0	3,164,364	2,669,263	54.2%
Gregory Shiferman	0	99,310	453,013	18.0%
Kimi Iguchi	0	703,620	0	100.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2024

Executive	Award	Shares unvested	Exercise price	Market value unvested
Gregory Shiferman	PSU	704	—	$3,823
Kimi Iguchi	Option	792	82.27	—
Laura Gault	Option	1,441	45.28	—
Gregory Shiferman	PSU	1,500	—	8,145
Gregory Shiferman	PSU	2,163	—	11,745
Laura Gault	PSU	2,170	—	11,783
Gregory Shiferman	PSU	3,000	—	16,290
Christopher Benecchi	Option	3,325	43.04	—
Gregory Shiferman	PSU	3,375	—	18,326
Christopher Benecchi	Option	3,562	31.36	—
Gregory Shiferman	PSU	4,125	—	22,399
Kimi Iguchi	Option	4,433	43.04	—
Gregory Shiferman	PSU	5,000	—	27,150
Gregory Shiferman	Option	6,000	23.02	—
Christopher Benecchi	PSU	6,250	—	33,938
Kimi Iguchi	PSU	6,650	—	36,110
Laura Gault	PSU	6,750	—	36,653
Kimi Iguchi	PSU	6,750	—	36,653
Christopher Benecchi	PSU	7,500	—	40,725
Gregory Shiferman	PSU	7,500	—	40,725
Laura Gault	PSU	7,500	—	40,725
Kimi Iguchi	PSU	7,500	—	40,725
Christopher Benecchi	PSU	7,750	—	42,083
Christopher Benecchi	PSU	8,100	—	43,983
Christopher Benecchi	Option	8,437	45.29	—
Kimi Iguchi	Option	9,057	45.28	—
Gregory Shiferman	Option	9,159	22.2	—
Christopher Benecchi	PSU	9,300	—	50,499
Gregory Shiferman	Option	10,000	6.05	—
Laura Gault	PSU	11,250	—	61,088
Kimi Iguchi	PSU	11,250	—	61,088
Christopher Benecchi	Option	11,321	45.28	—
Kimi Iguchi	PSU	12,400	—	67,332
Christopher Benecchi	Option	12,500	6.05	—
Christopher Benecchi	PSU	13,500	—	73,305
Laura Gault	PSU	13,500	—	73,305
Kimi Iguchi	PSU	13,500	—	73,305
Kimi Iguchi	PSU	13,640	—	74,065
Christopher Benecchi	PSU	15,750	—	85,523
Christopher Benecchi	PSU	16,200	—	87,966
Christopher Benecchi	PSU	17,050	—	92,582
Barry Greene	PSU	20,000	—	108,600
Barry Greene	Option	20,393	43.04	—
Laura Gault	Option	22,500	23.02	—
Kimi Iguchi	Option	22,500	23.02	—
Barry Greene	PSU	25,200	—	136,836
Christopher Benecchi	Option	27,000	23.02	—
Laura Gault	Option	29,521	37.88	—
Barry Greene	Option	36,021	45.28	—
Barry Greene	PSU	50,400	—	273,672
Laura Gault	PSU	52,545	—	285,319
Barry Greene	PSU	54,250	—	294,578
Barry Greene	PSU	57,040	—	309,727
Barry Greene	Option	168,000	23.02	—
Barry Greene	Option	455,000	85.82	—

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Jeffrey M. JonasIndependent · Departed during FY	$59,643	—	$91,810	—	$40,000	$191,453
Geno GermanoIndependent · Board Chair · Nominating and Corporate Governance (Chair)	98,682	—	91,810	—	0	190,492
James M. FratesIndependent · Audit (Chair) · Compensation	77,500	—	91,810	—	0	169,310
Michael F. ColaIndependent · Compensation (Chair) · Nominating and Corporate Governance	75,410	—	91,810	—	0	167,220
Elizabeth BarrettIndependent · Audit · Compensation	67,500	—	91,810	—	0	159,310
Jessica FedererIndependent · Audit	59,863	—	91,810	—	0	151,673
George GolumbeskiIndependent · Nominating and Corporate Governance	55,000	—	91,810	—	0	146,810
Steven PaulIndependent · Departed during FY	27,835	—	0	—	0	27,835
Kevin P. StarrIndependent · Departed during FY	1,161	—	0	—	0	1,161

Board fee structure and ownership guideline

Annual cash retainer	—
Annual equity retainer	—
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	—
Stock ownership guideline	stock ownership guidelines for our executives and non-employee directors, and a clawback policy to recover cash and equity incentive awards

Total cost of the board

Component	FY2024
Cash retainers and fees	$522,594
Equity awards (grant-date value)	$0
All other compensation	$40,000
Total cost of the board	$562,594

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Sage Therapeutics as a peer

Companies that benchmark against SAGE

14 companies name SAGE as a compensation peer

ACADIA PHARMACEUTICALS INCACADFY2025
Adaptive Biotechnologies CorpADPTFY2025
AGIOS PHARMACEUTICALS, INC.AGIOFY2025
Arcutis Biotherapeutics, Inc.ARQTFY2025
Aurinia Pharmaceuticals Inc.AUPHFY2025
AVADEL PHARMACEUTICALS PLCAVDLFY2024
BICYCLE THERAPEUTICS PLCBCYCFY2024
Biohaven Ltd.BHVNFY2025
Denali Therapeutics Inc.DNLIFY2025
ENANTA PHARMACEUTICALS INCENTAFY2025
Harmony Biosciences Holdings, Inc.HRMYFY2025
HERON THERAPEUTICS, INC. /DE/HRTXFY2025
Kiniksa Pharmaceuticals International, plcKNSAFY2025
PROTHENA CORP PUBLIC LTD COPRTAFY2025
Vanda Pharmaceuticals Inc.VNDAFY2025

Each company listed discloses SAGE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SAGE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

TVTX Travere TherapeuticsAGIO Agios Pharmaceuticals, Inc.CRSP CRISPR Therapeutics, Inc.AMLX Amylyx PharmaceuticalsALEC Alector, Inc.HALO Halozyme Therapeutics, Inc.FOLD Amicus Therapeutics, Inc.INSM Insmed, Inc.APLS Apellis Pharmaceuticals, Inc.AXSM Axsome Therapeutics, Inc.BPMC Blueprint Medicines CorporationSUPN Supernus Pharmaceuticals, Inc.RARE Ultragenyx Pharmaceutical Inc.EXEL Exelixis, Inc.ARDX ArdelyxDVAX Dynavax TechnologiesESPR Esperion TherapeuticsIRWD Ironwood PharmaceuticalsTARS Tarsus PharmaceuticalsRYTM Rhythm Pharmaceuticals, Inc.HRMY Harmony Biosciences Holdings, Inc. FibroGen, Inc.ACAD ACADIA Pharmaceuticals Inc.BCRX BioCryst PharmaceuticalsCERE Cerevel Therapeutics, Inc.DCPH Deciphera Pharmaceuticals, Inc.ITCI Intra-Cellular Therapies, Inc.MRTX Mirati Therapeutics, Inc. WeightPFGC PerformanceACAD ACADIA Pharmaceuticals Inc.CRSP CRISPR Therapeutics, Inc.AGIO Agios Pharmaceuticals, Inc.DCPH Deciphera Pharmaceuticals, Inc.ALKT Alector, Inc.HALO Halozyme Therapeutics, Inc.FOLD Amicus Therapeutics, Inc.HMY Harmony Biosciences Holdings, Inc.AMLX Amylyx PharmaceuticalsINSM Insmed, Inc.

Peer reciprocity

The companies Sage Therapeutics names as compensation peers that name it back in their own disclosed peer groups.

Agios Pharmaceuticals, Inc. (AGIO)¹²³Harmony Biosciences Holdings, Inc. (HRMY)¹²⁴ACADIA Pharmaceuticals Inc. (ACAD)¹²⁵Cerevel Therapeutics, Inc. (CERE)¹²⁶Intra-Cellular Therapies, Inc. (ITCI)¹²⁷

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Exelixis, Inc.	2025	Michael Morrissey	$1,306,040	$30,539,552	$0	$1,382,591	$33,239,183
2	Halozyme Therapeutics, Inc.	2025	Helen Torley	1,000,000	19,350,145	1,650,014	1,147,500	23,166,223
3	Rhythm Pharmaceuticals, Inc.	2025	David Meeker	807,692	8,274,785	7,688,560	759,488	17,544,525
4	Supernus Pharmaceuticals, Inc.	2025	Jack Khattar	1,036,000	6,535,029	7,031,545	846,930	15,501,557
5	Insmed, Inc.	2025	William Lewis	854,550	2,999,940	9,000,033	1,495,463	14,467,393
6	Blueprint Medicines Corporation	2024	Kathryn Haviland	821,363	7,472,480	4,315,144	854,217	13,477,004
7	BioCryst Pharmaceuticals	2025	Jon Stonehouse	728,466	0	11,132,458	1,052,633	12,951,082
8	Mirati Therapeutics, Inc.	2022	David Meek	749,423	6,043,885	4,233,427	438,985	11,937,371
9	Ultragenyx Pharmaceutical Inc.	2025	Emil Kakkis	861,100	8,364,938	1,847,356	299,663	11,405,535
10	Cerevel Therapeutics, Inc.	2022	N. Anthony Coles	642,735	0	10,085,985	496,706	11,225,426
11	Apellis Pharmaceuticals, Inc.	2024	Cedric Francois	793,193	4,779,832	4,787,768	0	10,957,451
12	Axsome Therapeutics, Inc.	2025	Herriot Tabuteau	835,000	5,533,554	2,833,237	876,750	10,283,492
13	Intra-Cellular Therapies, Inc.	2023	Sharon Mates	891,653	7,749,984	0	0	10,086,413
14	Amicus Therapeutics, Inc.	2024	Bradley Campbell	767,308	4,990,365	2,105,627	0	8,526,943
15	Travere Therapeutics	2025	Eric Dube	854,250	3,314,520	3,309,384	964,125	8,457,151
16	Acadia Pharmaceuticals Inc.	2025	Catherine Owen Adams	930,000	3,240,558	3,234,797	818,559	8,256,518
17	Dynavax Technologies	2024	Ryan Spencer	835,001	4,902,150	1,824,299	641,907	8,210,775
18	Harmony Biosciences Holdings, Inc.	2025	Jeffrey Dayno	743,600	1,976,520	4,599,000	558,000	7,899,535
19	Ardelyx	2025	Michael Raab	797,000	2,953,724	3,413,948	627,638	7,796,171
20	Crispr Therapeutics, Inc.	2025	Samarth Kulkarni	768,622	3,474,900	2,768,862	659,093	7,678,477
21	Alector, Inc.	2025	Alex Shootman	558,480	6,222,675	0	699,775	7,492,018
22	Performance	2026	Scott McPherson	880,385	4,250,191	0	1,933,218	7,129,941
23	Sage Therapeutics	2024	Barry Greene	830,712	3,164,364	2,669,263	431,970	7,112,589
24	Tarsus Pharmaceuticals	2025	Bobak Azamian	726,333	2,648,284	2,651,487	555,700	6,617,979
25	Deciphera Pharmaceuticals, Inc.	2023	Steven Hoerter	738,200	1,935,000	2,837,100	487,212	6,010,712
26	Agios Pharmaceuticals, Inc.	2025	Brian Goff	846,864	1,291,680	2,627,252	592,804	5,370,389
27	Esperion Therapeutics	2025	Sheldon Koenig	770,833	1,260,000	847,929	639,375	3,535,512
28	Amylyx Pharmaceuticals	2025	Justin Klee	686,200	650,226	817,783	548,098	2,719,807
29	Alector, Inc.	2025	Arnon Rosenthal	678,100	422,876	558,216	325,488	1,995,018
30	Ironwood Pharmaceuticals	2025	Thomas McCourt	867,568	411,696	0	650,676	1,948,390
—	Harmony Biosciences Holdings, Inc.	—	—	—	—	—	—	not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Sage Therapeutics	80%	not disclosed	Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index	Alpine Rewards
Acadia Pharmaceuticals Inc.	110%	Options 50 · PSU 25 · RSU 25	Yes	Frederic W. Cook & Co., Inc. (FW Cook)
Agios Pharmaceuticals, Inc.	100%	Option 40 · PSU 40 · RSU 20	No	Aon
Alector, Inc.	80%	not disclosed	not disclosed	Pearl Meyer & Partners, LLC
Alector, Inc.	125.3%	RSU 100	not disclosed	FW Cook
Amicus Therapeutics, Inc.	not disclosed	Option 33 · RSU 33 · PRSU 33	Yes — TSR Goal	Pay Governance
Amylyx Pharmaceuticals	106.5%	not disclosed	No	Pearl Meyer
Apellis Pharmaceuticals, Inc.	90.74%	RSU 50 · PSU 50	not disclosed	Pay Governance
Ardelyx	105%	Options 50 · RSU 50	not disclosed	Pearl Meyer
Axsome Therapeutics, Inc.	150%	RSU 33 · Options 33 · PSU 33	No	Frederic W. Cook & Co., Inc.
BioCryst Pharmaceuticals	not disclosed	not disclosed	not disclosed	Aon
Blueprint Medicines Corporation	130%	RSU 37 · Options 32 · PSU 31	Yes — Relative Total Stockholder Return (rTSR)	Aon
Cerevel Therapeutics, Inc.	128.8%	Options 100	not disclosed	Pay Governance LLC
Crispr Therapeutics, Inc.	not disclosed	not disclosed	not disclosed	Alpine Rewards, LLC
Deciphera Pharmaceuticals, Inc.	110%	Option 50 · PSU 50 · RSU 25	No	Pearl Meyer & Partners, LLC
Dynavax Technologies	102.5%	Options 34 · RSU 33 · PSU 33	Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index	Alpine
Esperion Therapeutics	110%	not disclosed	not disclosed	not disclosed
Exelixis, Inc.	105%	PSU 50 · RSU 50	Yes — 2025 Relative TSR Goal	Aon
Halozyme Therapeutics, Inc.	127.5%	PSU 50 · RSU 35 · Option 15	No	F.W. Cook & Co., Inc.
Harmony Biosciences Holdings, Inc.	100%	not disclosed	not disclosed	Pay Governance
Harmony Biosciences Holdings, Inc.	not disclosed	not disclosed	not disclosed	not disclosed
Insmed, Inc.	175%	Options 75 · RSU 25	No	Willis Towers Watson (WTW)
Intra-Cellular Therapies, Inc.	not disclosed	RSU 75 · PRSU 25	Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index	Aon Consulting, Inc.
Ironwood Pharmaceuticals	100%	RSU 50 · PSU 50	not disclosed	Alpine Rewards LLC
Mirati Therapeutics, Inc.	not disclosed	Option 50 · RSU 50	not disclosed	Aon Human Capital Solutions and Alpine Rewards
Performance	150.4%	PSU 60 · RSU 40	Yes — Relative TSR	Meridian Compensation Partners, LLC
Rhythm Pharmaceuticals, Inc.	120%	Options 50 · RSU 50	No	Pay Governance
Supernus Pharmaceuticals, Inc.	not disclosed	not disclosed	No	Aon
Tarsus Pharmaceuticals	108%	Options 50 · RSU 50	No	Pay Governance
Travere Therapeutics	150%	not disclosed	No	Aon
Ultragenyx Pharmaceutical Inc.	44%	PSU 60 · RSU 20 · Options 20	Yes — Relative TSR	Aon's Human Capital Solutions Practice

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2025	2025-04-16	35,986,261	10,918,957	348,822	76.72%	Passed
2024	2024-04-16	47,705,636	2,299,792	41,352	95.4%	Passed
2023	2023-04-17	39,995,146	11,173,607	39,894	78.16%	Passed
2021	2021-06-10	33,691,544	16,696,177	12,333	66.86%	Passed
2020	2020-06-09	26,623,925	16,643,658	17,523	61.53%	Passed
2019	2019-06-05	44,332,822	680,835	8,943	98.49%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2025	2025-04-16	76.72%^a
2024	2024-04-16	95.4%^b
2023	2023-04-17	78.16%^c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	19 : 1
CEO total compensation	$6,237,491
Median employee compensation	$337,122

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Elizabeth Barrett	Director	2025-06-11	A	21,500	$0	$0	Derivative, Class A Common	Form 4 ↗
Michael F. Cola	Director	2025-06-11	A	21,500	0	0	Derivative, Class A Common	Form 4 ↗
Jessica Federer	Director	2025-06-11	A	21,500	0	0	Derivative, Class A Common	Form 4 ↗
George Golumbeski	Director	2025-06-11	A	21,500	0	0	Derivative, Class A Common	Form 4 ↗
James M. Frates	Director	2025-06-11	A	21,500	0	0	Derivative, Class A Common	Form 4 ↗
Geno Germano	Director	2025-06-11	A	21,500	0	0	Derivative, Class A Common	Form 4 ↗
Gregory Shiferman	See Remarks	2025-06-24	D	79	9	728	Common	Form 4 ↗
Michael C. Quirk	See Remarks	2025-06-24	D	113	9	1,042	Common	Form 4 ↗
Barry Greene	Director	2025-07-31	D	46,940	—	—	Common	Form 4 ↗
James M. Frates	Director	2025-07-31	D	2,845	—	—	Common	Form 4 ↗
George Golumbeski	Director	2025-07-31	D	13,593	—	—	Derivative, Class A Common	Form 4 ↗
James M. Frates	Director	2025-07-31	D	21,500	—	—	Derivative, Class A Common	Form 4 ↗
Michael C. Quirk	See Remarks	2025-07-31	D	4,000	—	—	Derivative, Class A Common	Form 4 ↗
Gregory Shiferman	See Remarks	2025-07-31	D	7,215	—	—	Common	Form 4 ↗
Barry Greene	Director	2025-07-31	D	174,000	—	—	Derivative, Class A Common	Form 4 ↗
Gregory Shiferman	See Remarks	2025-07-31	D	10,000	—	—	Derivative, Class A Common	Form 4 ↗
Gregory Shiferman	See Remarks	2025-07-31	D	23,735	—	—	Common	Form 4 ↗
James M. Frates	Director	2025-07-31	D	19,154	—	—	Derivative, Class A Common	Form 4 ↗
George Golumbeski	Director	2025-07-31	D	21,500	—	—	Derivative, Class A Common	Form 4 ↗
George Golumbeski	Director	2025-07-31	D	8,000	—	—	Common	Form 4 ↗
Elizabeth Barrett	Director	2025-07-31	D	3,000	—	—	Common	Form 4 ↗
Michael F. Cola	Director	2025-07-31	D	21,500	—	—	Derivative, Class A Common	Form 4 ↗
Christopher Benecchi	Chief Operating Officer	2025-07-31	D	40,000	—	—	Derivative, Class A Common	Form 4 ↗
Christopher Benecchi	Chief Operating Officer	2025-07-31	D	36,375	—	—	Common	Form 4 ↗
Christopher Benecchi	Chief Operating Officer	2025-07-31	D	28,053	—	—	Common	Form 4 ↗
Jessica Federer	Director	2025-07-31	D	21,500	—	—	Derivative, Class A Common	Form 4 ↗
Michael C. Quirk	See Remarks	2025-07-31	D	36,000	—	—	Derivative, Class A Common	Form 4 ↗
Michael C. Quirk	See Remarks	2025-07-31	D	7,962	—	—	Common	Form 4 ↗
Michael C. Quirk	See Remarks	2025-07-31	D	24,999	—	—	Common	Form 4 ↗
Christopher Benecchi	Chief Operating Officer	2025-07-31	D	12,500	—	—	Derivative, Class A Common	Form 4 ↗
Barry Greene	Director	2025-07-31	D	53,229	—	—	Common	Form 4 ↗
Elizabeth Barrett	Director	2025-07-31	D	21,500	—	—	Derivative, Class A Common	Form 4 ↗
Geno Germano	Director	2025-07-31	D	21,500	—	—	Derivative, Class A Common	Form 4 ↗
Gregory Shiferman	See Remarks	2025-07-31	D	28,000	—	—	Derivative, Class A Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (127 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Barry Greene. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · page 48. As printed: 7,112,589. View filing ↗
Section 01, Kimi Iguchi. DEF 14A, filed 2025-04-24. Section “Executive Compensation”. As printed: 3,067,675. View filing ↗
Section 01, Christopher Benecchi. DEF 14A, filed 2025-04-24. Section “Executive Compensation”. As printed: 2,604,988. View filing ↗
Section 01, Anne Marie Cook. DEF 14A, filed 2025-04-24. Section “Executive Compensation”. As printed: 2,581,710. View filing ↗
Section 01, Laura Gault. DEF 14A, filed 2025-04-24. Section “Executive Compensation”. As printed: 2,203,053. View filing ↗
Section 01, Gregory Shiferman. DEF 14A, filed 2025-04-24. Section “Executive Compensation”. As printed: 1,169,668. View filing ↗
Section 03, Senior Vice PSU. DEF 14A, filed 2025-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Christopher Benecchi OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Christopher Benecchi PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Christopher Benecchi PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Christopher Benecchi OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Laura Gault PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Laura Gault OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Barry Greene PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Gregory Shiferman OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Senior Vice OPTION. DEF 14A, filed 2025-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Christopher Benecchi PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Gregory Shiferman PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Christopher Benecchi PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Senior Vice OPTION. DEF 14A, filed 2025-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Laura Gault PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Laura Gault PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Barry Greene PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Kimi Iguchi PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Gregory Shiferman PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Barry Greene OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Gregory Shiferman OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Gregory Shiferman OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2024-04-24. Section “CEO Pay Ratio”. As printed: 19 : 1. View filing ↗
Section 08, Jeffrey M. Jonas. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 191,453. View filing ↗
Section 08, Geno Germano. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 190,492. View filing ↗
Section 08, James M. Frates. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 169,310. View filing ↗
Section 08, Michael F. Cola. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 167,220. View filing ↗
Section 08, Elizabeth Barrett. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 159,310. View filing ↗
Section 08, Jessica Federer. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 151,673. View filing ↗
Section 08, George Golumbeski. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 146,810. View filing ↗
Section 08, Steven Paul. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 27,835. View filing ↗
Section 08, Kevin P. Starr. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 1,161. View filing ↗
Section 02, Elizabeth Barrett 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael F. Cola 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jessica Federer 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George Golumbeski 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James M. Frates 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Geno Germano 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gregory Shiferman 2025-06-24. Form 4, filed 2025-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael C. Quirk 2025-06-24. Form 4, filed 2025-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Barry Greene 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James M. Frates 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George Golumbeski 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James M. Frates 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael C. Quirk 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gregory Shiferman 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Barry Greene 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gregory Shiferman 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gregory Shiferman 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James M. Frates 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George Golumbeski 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George Golumbeski 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Elizabeth Barrett 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael F. Cola 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Benecchi 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Benecchi 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Benecchi 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jessica Federer 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael C. Quirk 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael C. Quirk 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael C. Quirk 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Benecchi 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Barry Greene 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Elizabeth Barrett 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Geno Germano 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gregory Shiferman 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 76.72% (votes for as printed: 35,986,261). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-06-11. Item 5.07 · say-on-pay result. As reported: 95.4% (votes for as printed: 47,705,636). View filing ↗
Section 06, 2023 vote. Form 8-K, filed 2023-06-16. Item 5.07 · say-on-pay result. As reported: 78.16% (votes for as printed: 39,995,146). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 522,594 + equity 0 + all other 40,000 = 562,594, summed across the director compensation table rows.
Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
Halozyme Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. View filing ↗
Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
Supernus Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. View filing ↗
Insmed, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Insmed, Inc.'s own proxy. As printed: 14,467,393. View filing ↗
Blueprint Medicines Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. View filing ↗
BioCryst Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals's own proxy. As printed: 12,951,082. View filing ↗
Mirati Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-06. CEO total compensation as printed in Mirati Therapeutics, Inc.'s own proxy. As printed: 11,937,371. View filing ↗
Ultragenyx Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. View filing ↗
Cerevel Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-28. CEO total compensation as printed in Cerevel Therapeutics, Inc.'s own proxy. As printed: 11,225,426. View filing ↗
Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
Axsome Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. View filing ↗
Intra-Cellular Therapies, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. View filing ↗
Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
Travere Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. View filing ↗
Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
Dynavax Technologies, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. View filing ↗
Harmony Biosciences Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Harmony Biosciences Holdings, Inc.'s own proxy. As printed: 7,899,535. View filing ↗
Ardelyx, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. View filing ↗
Crispr Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Crispr Therapeutics, Inc.'s own proxy. As printed: 7,678,477. View filing ↗
Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 7,492,018. View filing ↗
Performance, Section 10b CEO total. DEF 14A, filed 2026-10-09. CEO total compensation as printed in Performance's own proxy. As printed: 7,129,941. View filing ↗
Sage Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. View filing ↗
Tarsus Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Tarsus Pharmaceuticals's own proxy. As printed: 6,617,979. View filing ↗
Deciphera Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Deciphera Pharmaceuticals, Inc.'s own proxy. As printed: 6,010,712. View filing ↗
Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
Esperion Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Esperion Therapeutics's own proxy. As printed: 3,535,512. View filing ↗
Amylyx Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Amylyx Pharmaceuticals's own proxy. As printed: 2,719,807. View filing ↗
Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗
Ironwood Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. View filing ↗
Section 10a, Agios Pharmaceuticals, Inc. reciprocity. DEF 14A. Agios Pharmaceuticals, Inc. names Sage Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Harmony Biosciences Holdings, Inc. reciprocity. DEF 14A. Harmony Biosciences Holdings, Inc. names Sage Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, ACADIA Pharmaceuticals Inc. reciprocity. DEF 14A. ACADIA Pharmaceuticals Inc. names Sage Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Cerevel Therapeutics, Inc. reciprocity. DEF 14A. Cerevel Therapeutics, Inc. names Sage Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Intra-Cellular Therapies, Inc. reciprocity. DEF 14A. Intra-Cellular Therapies, Inc. names Sage Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗